Search Within

Shanu Modi

Formats
  1. Meeting Abstract (151)
  2. Journal Article (101)
  3. Review (11)
  4. Correspondence (2)
  5. Editorial (2)
  6. Research Letter (1)
Groups
  1. Breast Medicine Service (268)
  2. Department of Medicine (268)
  3. Solid Tumor Oncology Division (268)
  4. Survivorship Research (114)
  5. GSK Faculty (107)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (90)

More Groups

People
  1. Clifford Hudis (79)
  2. Larry Norton (53)
  3. Sarat Chandarlapaty (51)
  4. Sujata Patil (44)
  5. Chau Dang (42)
  6. Komal Jhaveri (35)

More People

Years
  1. 2025 (8)
  2. 2024 (23)
  3. 2023 (15)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (21)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (50)
  3. Annals of Oncology (27)
  4. Breast Cancer Research and Treatment (14)
  5. Clinical Cancer Research (10)
  6. Clinical Breast Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (68)
  2. American Association for Cancer Research (64)
  3. Oxford University Press (33)
  4. Elsevier Inc. (19)
  5. Springer (18)
  6. Nature Publishing Group (13)

More Publishers

Results (268)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • VICKI: A phase Ib/II, randomized, placebo-controlled, study of venetoclax plus ado-trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC)
    Meeting Abstract

    Lindeman, G. J.; Hamilton, E.; Krop, I.; Lim, B.; Modi, S.; Saura, C.; Desai, R.; Danner, B. J.; Fernando, T. M.; Kong, S.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer
    Meeting Abstract

    Beckwith, H. C.; Medgyesy, D. C.; Abraham, J.; Nanda, R.; Tkaczuk, K. H. R.; Krop, I. E.; Pusztai, L.; Modi, S.; Mita, M. M.; Specht, J. M.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Impact of online education regarding novel HER2 therapies on translating evidence to practice
    Meeting Abstract

    Parikh, K.; Dorkhom, N.; Chen, P.; Cameron, D. R.; Caraico, R.; Hanley, K.; Modi, S.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A phase I study
    Journal Article

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S. W.; Slovin, S. F.; Adamow, M.; Blinder, V. S.; Brahmachary, M.; Carlsen, M.; Comen, E.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients
    Meeting Abstract

    Pusztai, L.; Lu, H.; Hale, C.; Grosse-Wilde, A.; Specht, J.; Modi, S.; Han, H.; Cortes, J.; Oliveira, M.; Garfin, P.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • Phase Ib dose-escalation/expansion trial of ribociclib in combination with everolimus and exemestane in postmenopausal women with HR(+), HER2(-) advanced breast cancer
    Journal Article

    Bardia, A.; Modi, S.; Oliveira, M.; Cortes, J.; Campone, M.; Ma, B.; Dirix, L.; Weise, A.; Hewes, B.; Diaz-Padilla, I.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 study
    Meeting Abstract

    Krop, I.; Manich, C. S.; Yamashita, T.; Park, Y. H.; Kim, S. B. K.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; more...
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
    Meeting Abstract

    Zaman, K.; Modi, S.; Ohtan, S.; Lee, C.; Wang, Y.; Saxena, K.; Cameron, D. A.
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • Measuring tumor epichaperome expression using [(124)I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer
    Journal Article

    Jhaveri, K. L.; dos Anjos, C. H.; Taldone, T.; Wang, R.; Comen, E.; Fornier, M.; Bromberg, J. F.; Ma, W.; Patil, S.; Rodina, A.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save